This study will demonstrate the efficacy, safety and tolerability of Siponimod compared to placebo in patients with secondary progressive multiple sclerosis (SPMS), a population currently in need of improved treatment options. Study medication is dosed as a once-daily oral tablet.

• Women and men ages 18 to 60 years old, with a prior history of relapsing remitting MS, who are currently diagnosed with secondary progressive multiple sclerosis (SPMS) may qualify for this investigational drug study.
• Other eligibility criteria are based on neurological test results.

Contact Anne McDonald, RN or Kathleen Allain, LPN at 508-368-3929 for more information.